Form 4: Atara Biotherapeutics CEO Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Atara Biotherapeutics CEO Pascal Touchon sold shares to cover tax withholding obligations related to vesting restricted stock units.
Summary
- On August 16, 2024, Pascal Touchon, the President and CEO of Atara Biotherapeutics, sold 2,762 shares of common stock at a price of $6.629 and 276 shares of common stock at a price of $6.63.
- The sales were executed to satisfy tax withholding obligations related to the vesting of previously granted restricted stock units.
- Following the transactions, Touchon directly owns 70,127 shares of Atara Biotherapeutics common stock.
- The reported amount reflects the 1:25 reverse stock split effected by the Issuer on June 20, 2024.
Sentiment
Score: 5
Explanation: This is a neutral event. The CEO sold shares to cover tax obligations, which is a common practice. It doesn't necessarily indicate a positive or negative outlook for the company.
Industry Context
This is a routine Form 4 filing, which is common for corporate executives who sell shares of their company's stock. It is important to note that this sale was to cover tax obligations and may not reflect a change in the executive's long-term outlook for the company.
Stakeholder Impact
- The stock sale could have a minor impact on shareholders due to the slight dilution of shares.
Key Dates
| Date | Description |
|---|---|
| June 20, 2024 | 1:25 reverse stock split effected by the Issuer |
| August 16, 2024 | Pascal Touchon sold shares of common stock |
| August 20, 2024 | Date of signature for the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.